KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeMD (LFMD) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for LifeMD (LFMD) over the last 14 years, with Q3 2025 value amounting to $23.8 million.

  • LifeMD's Cash & Equivalents fell 3668.07% to $23.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.8 million, marking a year-over-year decrease of 3668.07%. This contributed to the annual value of $35.0 million for FY2024, which is 560.6% up from last year.
  • Per LifeMD's latest filing, its Cash & Equivalents stood at $23.8 million for Q3 2025, which was down 3668.07% from $36.2 million recorded in Q2 2025.
  • Over the past 5 years, LifeMD's Cash & Equivalents peaked at $41.3 million during Q4 2021, and registered a low of $4.0 million during Q4 2022.
  • Its 5-year average for Cash & Equivalents is $23.0 million, with a median of $23.8 million in 2025.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 508048.05% in 2021, then crashed by 9042.07% in 2022.
  • LifeMD's Cash & Equivalents (Quarter) stood at $41.3 million in 2021, then plummeted by 90.42% to $4.0 million in 2022, then soared by 737.26% to $33.1 million in 2023, then grew by 5.61% to $35.0 million in 2024, then tumbled by 32.01% to $23.8 million in 2025.
  • Its Cash & Equivalents was $23.8 million in Q3 2025, compared to $36.2 million in Q2 2025 and $34.4 million in Q1 2025.